| Product Code: ETC10756542 | Publication Date: Apr 2025 | Updated Date: Aug 2025 | Product Type: Market Research Report | |
| Publisher: 6Wresearch | No. of Pages: 65 | No. of Figures: 34 | No. of Tables: 19 | |
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 Austria PD-1 Non-Small Cell Lung Cancer Market Overview |
3.1 Austria Country Macro Economic Indicators |
3.2 Austria PD-1 Non-Small Cell Lung Cancer Market Revenues & Volume, 2021 & 2031F |
3.3 Austria PD-1 Non-Small Cell Lung Cancer Market - Industry Life Cycle |
3.4 Austria PD-1 Non-Small Cell Lung Cancer Market - Porter's Five Forces |
3.5 Austria PD-1 Non-Small Cell Lung Cancer Market Revenues & Volume Share, By Drug Type, 2021 & 2031F |
3.6 Austria PD-1 Non-Small Cell Lung Cancer Market Revenues & Volume Share, By Therapy Type, 2021 & 2031F |
3.7 Austria PD-1 Non-Small Cell Lung Cancer Market Revenues & Volume Share, By Treatment Stage, 2021 & 2031F |
3.8 Austria PD-1 Non-Small Cell Lung Cancer Market Revenues & Volume Share, By Mode of Action, 2021 & 2031F |
3.9 Austria PD-1 Non-Small Cell Lung Cancer Market Revenues & Volume Share, By End User, 2021 & 2031F |
4 Austria PD-1 Non-Small Cell Lung Cancer Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.2.1 Increasing prevalence of non-small cell lung cancer in Austria |
4.2.2 Rising adoption of PD-1 inhibitors for lung cancer treatment |
4.2.3 Advances in immunotherapy research and development |
4.3 Market Restraints |
4.3.1 High cost associated with PD-1 inhibitors |
4.3.2 Stringent regulatory requirements for drug approval |
4.3.3 Competition from other treatment options like chemotherapy |
5 Austria PD-1 Non-Small Cell Lung Cancer Market Trends |
6 Austria PD-1 Non-Small Cell Lung Cancer Market, By Types |
6.1 Austria PD-1 Non-Small Cell Lung Cancer Market, By Drug Type |
6.1.1 Overview and Analysis |
6.1.2 Austria PD-1 Non-Small Cell Lung Cancer Market Revenues & Volume, By Drug Type, 2021 - 2031F |
6.1.3 Austria PD-1 Non-Small Cell Lung Cancer Market Revenues & Volume, By PD-1 Inhibitors, 2021 - 2031F |
6.1.4 Austria PD-1 Non-Small Cell Lung Cancer Market Revenues & Volume, By PD-L1 Inhibitors, 2021 - 2031F |
6.1.5 Austria PD-1 Non-Small Cell Lung Cancer Market Revenues & Volume, By Combination Therapy, 2021 - 2031F |
6.1.6 Austria PD-1 Non-Small Cell Lung Cancer Market Revenues & Volume, By Monotherapy, 2021 - 2031F |
6.1.7 Austria PD-1 Non-Small Cell Lung Cancer Market Revenues & Volume, By Adjuvant Therapy, 2021 - 2031F |
6.2 Austria PD-1 Non-Small Cell Lung Cancer Market, By Therapy Type |
6.2.1 Overview and Analysis |
6.2.2 Austria PD-1 Non-Small Cell Lung Cancer Market Revenues & Volume, By Immunotherapy, 2021 - 2031F |
6.2.3 Austria PD-1 Non-Small Cell Lung Cancer Market Revenues & Volume, By Chemotherapy, 2021 - 2031F |
6.2.4 Austria PD-1 Non-Small Cell Lung Cancer Market Revenues & Volume, By Radiation Therapy, 2021 - 2031F |
6.2.5 Austria PD-1 Non-Small Cell Lung Cancer Market Revenues & Volume, By Surgery, 2021 - 2031F |
6.2.6 Austria PD-1 Non-Small Cell Lung Cancer Market Revenues & Volume, By Palliative Care, 2021 - 2031F |
6.3 Austria PD-1 Non-Small Cell Lung Cancer Market, By Treatment Stage |
6.3.1 Overview and Analysis |
6.3.2 Austria PD-1 Non-Small Cell Lung Cancer Market Revenues & Volume, By First-Line Treatment, 2021 - 2031F |
6.3.3 Austria PD-1 Non-Small Cell Lung Cancer Market Revenues & Volume, By Second-Line Treatment, 2021 - 2031F |
6.3.4 Austria PD-1 Non-Small Cell Lung Cancer Market Revenues & Volume, By Advanced-Stage Treatment, 2021 - 2031F |
6.3.5 Austria PD-1 Non-Small Cell Lung Cancer Market Revenues & Volume, By Recurrent Cancer Treatment, 2021 - 2031F |
6.3.6 Austria PD-1 Non-Small Cell Lung Cancer Market Revenues & Volume, By Metastatic Cancer Treatment, 2021 - 2031F |
6.4 Austria PD-1 Non-Small Cell Lung Cancer Market, By Mode of Action |
6.4.1 Overview and Analysis |
6.4.2 Austria PD-1 Non-Small Cell Lung Cancer Market Revenues & Volume, By Targeted Therapy, 2021 - 2031F |
6.4.3 Austria PD-1 Non-Small Cell Lung Cancer Market Revenues & Volume, By Checkpoint Inhibitors, 2021 - 2031F |
6.4.4 Austria PD-1 Non-Small Cell Lung Cancer Market Revenues & Volume, By Biomarker-Based Therapy, 2021 - 2031F |
6.4.5 Austria PD-1 Non-Small Cell Lung Cancer Market Revenues & Volume, By Immune Checkpoint Modulation, 2021 - 2031F |
6.4.6 Austria PD-1 Non-Small Cell Lung Cancer Market Revenues & Volume, By T-Cell Activation, 2021 - 2031F |
6.5 Austria PD-1 Non-Small Cell Lung Cancer Market, By End User |
6.5.1 Overview and Analysis |
6.5.2 Austria PD-1 Non-Small Cell Lung Cancer Market Revenues & Volume, By Hospitals, 2021 - 2031F |
6.5.3 Austria PD-1 Non-Small Cell Lung Cancer Market Revenues & Volume, By Research Labs, 2021 - 2031F |
6.5.4 Austria PD-1 Non-Small Cell Lung Cancer Market Revenues & Volume, By Oncology Centers, 2021 - 2031F |
6.5.5 Austria PD-1 Non-Small Cell Lung Cancer Market Revenues & Volume, By Clinics, 2021 - 2031F |
6.5.6 Austria PD-1 Non-Small Cell Lung Cancer Market Revenues & Volume, By Diagnostic Centers, 2021 - 2031F |
7 Austria PD-1 Non-Small Cell Lung Cancer Market Import-Export Trade Statistics |
7.1 Austria PD-1 Non-Small Cell Lung Cancer Market Export to Major Countries |
7.2 Austria PD-1 Non-Small Cell Lung Cancer Market Imports from Major Countries |
8 Austria PD-1 Non-Small Cell Lung Cancer Market Key Performance Indicators |
8.1 Patient response rate to PD-1 inhibitors |
8.2 Number of clinical trials evaluating PD-1 inhibitors in Austria |
8.3 Rate of adoption of immunotherapy in lung cancer treatment |
8.4 Average time to market for new PD-1 inhibitors in Austria |
8.5 Number of oncologists trained in prescribing PD-1 inhibitors |
9 Austria PD-1 Non-Small Cell Lung Cancer Market - Opportunity Assessment |
9.1 Austria PD-1 Non-Small Cell Lung Cancer Market Opportunity Assessment, By Drug Type, 2021 & 2031F |
9.2 Austria PD-1 Non-Small Cell Lung Cancer Market Opportunity Assessment, By Therapy Type, 2021 & 2031F |
9.3 Austria PD-1 Non-Small Cell Lung Cancer Market Opportunity Assessment, By Treatment Stage, 2021 & 2031F |
9.4 Austria PD-1 Non-Small Cell Lung Cancer Market Opportunity Assessment, By Mode of Action, 2021 & 2031F |
9.5 Austria PD-1 Non-Small Cell Lung Cancer Market Opportunity Assessment, By End User, 2021 & 2031F |
10 Austria PD-1 Non-Small Cell Lung Cancer Market - Competitive Landscape |
10.1 Austria PD-1 Non-Small Cell Lung Cancer Market Revenue Share, By Companies, 2024 |
10.2 Austria PD-1 Non-Small Cell Lung Cancer Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations |
13 Disclaimer |
Export potential enables firms to identify high-growth global markets with greater confidence by combining advanced trade intelligence with a structured quantitative methodology. The framework analyzes emerging demand trends and country-level import patterns while integrating macroeconomic and trade datasets such as GDP and population forecasts, bilateral import–export flows, tariff structures, elasticity differentials between developed and developing economies, geographic distance, and import demand projections. Using weighted trade values from 2020–2024 as the base period to project country-to-country export potential for 2030, these inputs are operationalized through calculated drivers such as gravity model parameters, tariff impact factors, and projected GDP per-capita growth. Through an analysis of hidden potentials, demand hotspots, and market conditions that are most favorable to success, this method enables firms to focus on target countries, maximize returns, and global expansion with data, backed by accuracy.
By factoring in the projected importer demand gap that is currently unmet and could be potential opportunity, it identifies the potential for the Exporter (Country) among 190 countries, against the general trade analysis, which identifies the biggest importer or exporter.
To discover high-growth global markets and optimize your business strategy:
Click Here